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Abstract
Background:  Use of synbiotic preparations as dietary supplement is believed to be a valid
approach to restore and maintain colonic microflora. However, only few papers have been
published on the assessment of these food supplements and none of them have used molecular
biology techniques to evaluate the effects of the probiotic components.
Methods: Twelve healthy volunteers were recruited. Faecal samples were taken before and at
various time points during the administration period and at day 3 in the post-treatment period.
Stool culture were performed and amplified ribosomal DNA restriction analysis was used to detect
L. paracasei, the major bacterial component of the synbiotic products.
Results: An increase of at least 1 log of L. paracasei-like bacteria was observed in all subjects. An
increase of as much as 3 log was seen in subjects who had a low number of L. paracasei-like
lactobacilli at the baseline. The counts of L. paracasei-like lactobacilli were found to persist for at
least 3 days after discontinuation of intake in healthy volunteers in 7 subjects. Genetic analysis
showed that the maiority of vancomicin insensitive lactobacilli were real L. paracasei, as the strains
administered with the tested product.
Conclusion: This study has shown that the strains of L paracasei administered with a synbiotic
dietary supplement are able to survive through the gastrointestinal tract and to persist for at least
a few days. It was also shown the efficacy of a synbiotic preparation to positively affect the
microflora of healthy volunteers.
Background
For a long time colonic microflora has been considered to
play an important role in the maintenance of the health
and well-being of the host [1]. In addition to promote
normal gastrointestinal functions and protecting against
pathogenic bacteria, the microflora exerts beneficial
effects on systemic metabolism and immune system [2].
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The ability to control the growth and the pathogenic
potential of these bacteria depends on the proper function
of the microflora [3].
Imbalance in the colonic microflora with relative predom-
inance of aggressive bacteria and insufficient concentra-
tion of protective species has been associated with colonic
inflammation [4,5] and pouchitis[6].
Intake of probiotics (living micro-organisms), prebiotics
(non-digestible oligosaccharides) and synbiotics (mixture
of probiotics and prebiotics) has been demonstrated to
modify the composition of the microflora, restore the
microbial balance and therefore have the potential to pro-
vide health benefits [7–9]. However it has only been dur-
ing the last few years that well designed clinical studies
have provided clear evidence of health promoting effects,
such as prevention of antibiotic-associated diarrhoea [10],
treatment of acute diarrhoea[11], inflammatory bowel
disease[12], eradication of C difficile infection[13] and
enhancement of intestinal immunity [14,15].
The current state of evidence suggests that probiotic effects
are strain-specific and even strains belonging to the same
species may have marked or no probiotic effect [16].
As a result, in recent years there has been an increasing
demand to select, by means of in vitro and in vivo tests,
new strains with potential superior probiotic effects [17].
There is a general consensus that probiotic strains should
be of human origin, as these bacteria have a greater chance
of competing with resident bacteria, and of becoming
numerically predominant after short intake and to persist
in the colonic environment for some time after discontin-
uation of use.
Prebiotic substances are non digestible food ingredients
which could be fermented by selected groups of beneficial
bacteria; their positive influence on intestinal flora has
been assed by a number of studies (for a review see [18])
The use of probiotic strains together with prebiotic sub-
stances will provide a combined effect, named "synbiotic"
[19].
A large number of new lactobacilli strains have been pre-
viously isolated from faecal samples of newborns [20];
they were identified, by means of genetic analysis, as nat-
urally persisting in the same subjects for several following
days [20]. Following phenotypic characterisation and in
vitro evaluation, three new lactobacilli strains (L. paracasei
strain B 21060, L. paracasei B21070 and L. gasseri strain
B21090) have finally selected in view of their use as
probiotics.
A synbiotic formulation, consisting of a mixture of the
above selected strains, oligosaccharides as prebiotic ingre-
dients, glutamin, vitamin B6 and zinc, has been devel-
oped. The rationale of this formulation is to exploit a
complementary probiotic action resulting from the differ-
ent intrinsic properties of each individual strain and the
promotion of bifidobacterial growth due to oligosaccha-
rides. This formulation has been here assessed in a nutri-
tional trial aimed at evaluating the ability of the selected
strains to survive, grow and persist along the gastrointesti-
nal tract and its efficacy and safety in various gastrointes-
tinal disorders when administered in the final
pharmaceutical formulation, in order to follow the
recently issued FAO/WHO guidelines [16].
The primary aim of this study was to evaluate the ability
of the probiotic strains delivered by the synbiotic prepara-
tion to survive following passage through the gastrointes-
tinal tract and to persist in the stools after discontinuation
of the intake in healthy volunteers.
The secondary aim was to evaluate the effects of the syn-




Twelve healthy volunteers participated in this study. Eligi-
ble participants were of both sexes and aged 24–48 years.
Subjects were considered healthy on entry into the study
if they did not have a history of chronic gastrointestinal
diseases including chronic constipation and any episode
of diarrhoea (> 3 bowel movements/day for 3 consecutive
days) during the last month and did not present any cur-
rent sign or symptom of gastrointestinal disorder or infec-
tion. Individuals were not included in the study if they
were pregnant or breast-feeding, had a history of diabetes
or had received antibiotics over the last 3 months before
admission.
Subjects taking probiotic preparations including fer-
mented milk had to discontinue the intake at least 2
weeks before entry into the study. Standard yoghurt, con-
taining  Lactobacillus bulgaricus and/or  Streptococcus ther-
mophilus  only, was not prohibited. Before entry, all
participants were screened medically for their suitability
for the study.
Each subject signed an informed consent after he/she had
been made fully aware of the purpose of the study.
Synbiotic administration
For the present study we used a new synbiotic preparation
containing a combination of viable freeze-dried new
lactobacilli strains of human origin with prebioticsNutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/11
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(inuline, oligosaccharides), glutamine, zinc and vitamin
B6.
The product was available as a powder and dispensed in
6-g bag. Each bag contained 5 × 109 of both L. paracasei
strain B21060 and strain B21070 and 0.5 × 109 of L. gasseri
strain B 21090 [Flortec, Bracco SpA, Milan]. Each subject
was instructed to take one bag three times a day (before
breakfast, lunch and dinner) for 15 days. The content of
the powder had to be dissolved in 50 ml of water before
oral intake.
Strains are deposited at the Collection Nationale de Cul-
tures de Microorganismes, Institute Pasteur (Paris).
Study procedures
The study had three periods: 7-day screening and baseline
period (day-7 till day 0), 15-day intake period (day 1-day
15) and 3-day post-treatment period (day +1-day+3) Sub-
jects' medical history, physical examination, and routine
laboratory tests were taken at day-7. Faecal samples were
collected at day-7 and day 0.
During the administration period subjects returned to
deliver stool samples collected at day 5, 10 and 15, a gen-
eral daily questionnaire on daily well-being, stool consist-
ency and frequency and verification of compliance to the
study procedures. Information on tolerability and possi-
ble adverse events was recorded at each visit.
In the post-treatment period subjects returned to deliver
stool samples collected at day +3. The faecal samples were
collected in sterile disposables with 9 ml of AMIES liquid
(Difco, Detroit, Michigan), stored at 4–8°C and delivered
to the Department of Microbiology within 12 hours after
collection.
Microbiological analysis of faeces
Processing of samples occurred within 12 hours after
collection.
Weighted samples (about 1 g) were homogenised for 30 s
in a stomacher (Stomacher 400, Seward, London, Eng-
land) before dilution in a pre-reduced brain hearth infu-
sion broth and cultivation on the appropriate selective
media.
Appropriate dilutions were plated using Rogosa Acetate
agar (Difco) and Rogosa Acetate agar (Difco) added with
12  µg/ml of vancomycin (Sigma) to enumerate total
Lactobacillus spp. and vancomicyn insensitive lactobacilli
(i.e. L. paracasei group, including L. paracasei, L. casei and
L. rhamnosus), respectively.
Bifidobacterium strains were enumerated using TPY agar
added with 12 µg/ml of nalidixic acid (Sigma, St. Louis,
USA), while enterobacteria were counted on VRBA, ente-
rocci on SB agar and Cl. perfringens was counted on
Clostridium perfrigens agar base.
All plates for lactobacilli were incubated for 48 hrs at
37°C in anaerobic jars (GasPak, BBL, Coskeysville, MD,
USA), while the incubation for clostridia was extended to
3 days. Enterocci were incubated in aerobic conditions for
24 hours and enterobacteriaceae for 12 hours.
Genetic identification of L. paracasei
PCR-ARDRA (amplified ribosomal DNA restriction analy-
sis) was performed to identify species among the vanco-
mycin-insensitive  Lactobacillus  colonies (L. paracasei
group). We used a set of four enzymes and five primers to
amplify the 16S-rDNA sequences of the tested lactobacilli.
This is a reliable and rapid method to recognise L. paraca-
sei strains from L. casei and L. rhamnosus [21].
L. gasseri was not sought due to the lack of a selective
medium with antibiotics able to reduce the number of
CFUs to be checked by means of genetic analysis.
Study endpoints
In the planning of the study the ability to survive passage
through the gastrointestinal tract was defined as successful
if an increase of least one log in the counts of L. paracasei
group was observed in the stool sample at the end of treat-
ment compared to baseline. Persistence was considered
adequate if the concentration in the faecal sample after a
3-day discontinuation of intake was equal or only slightly
decreased (max 1 log) compared to end of treatment.
In addition, an increase of total lactobacilli and Bifidobac-
terium and a decrease of Enterobacteriacee, enterococci and




All the 12 subjects (5 M, 7 F, range 24 to 48 years old)
completed the study. The preparation was tolerated and
accepted very well by each participant. No adverse effect
was registered during the study.
The microbiology examination of faecal samples showed
an increase of at least 1 log of L. paracasei group in all sub-
jects over the intake period. The increase in the counts was
rapid and mostly evident after 5 day-administration. Six
subjects who had a low number of counts of L. casei group
at the baseline had in increase of even 3 log during the
intake (Table 1).Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/11
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In the post administration period, the counts of L. paraca-
sei group in 7 subjects were similar to those achieved at
the end of treatment whereas in 5 subjects a decrease of
more than one log was found. At the same timepoint, only
3 subjects had low counts (< 105) of L. paracasei group
compared to 7 subjects in the baseline period (Table 2).
In 8 out of 12 subjects, an increase of at least one log was
observed in the counts of bifidobacteria at end of treat-
ment compared to the baseline sample. In half of the sub-
jects an increase of 3 log was observed. Similarly, an
increase of total lactobacilli was found in 9 subjects at end
of treatment (Table 1).
No consistent changes were found in the counts of Entero-
bacteriacee, enterococci and Clostridium during the study.
Genetic identification of L. paracasei
Genetic analysis was carried out to identify and quantify
isolates L. paracasei really belonging to this species among
all the vancomicin insensitive CFU of lactobacilli. Results
actually showed that most of them were L. paracasei (Fig.
1). In fact 60 out of 65 (92%) CFU at 10-day, 49 out of 58
(84%) CFU at 15-day and 105 out of 132 (80%) vanc-
omicin CFU at 3-day post-administration were L. paracasei
(Table 3).
Discussion
A novel synbiotic preparation has been assessed by means
of an in vivo nutritional trial. Quite surprisingly, only two
papers are available on the assessment of the efficacy of
synbiotic products [22,23] and none of them have used
genetic tools to monitor the fate of the probiotic bacteria.
Strains used in this work have been carefully selected by
the most commonly used in vitro tests for the study of pro-
biotic strains [24]. Three strains, L. paracasei B21060, B
21070 and L. gasseri B21190 have finally been selected.
These strains have shown a resistance to gastric acidity
equal or superior to the reference strains. Similar results
were obtained in bile acid resistance tests.
Adhesion to human epithelial cells (buccal cells and intes-
tinal cells) was previously assessed [24] and shows that
adhesion is more pronounced for B21060 and 21070
than for B21190 and reference strains (ATCC 53103 and
ATCC 23850).
Following the screening period, a combination of the
selected probiotics were included in a synbiotic prepara-
tion with oligosaccharides, glutamin, vitamin B6 and
zinc.
Table 1: Changes in the counts of lactobacilli and bifidobacteria following intake of synbiotic preparation. Individual values. Values are 
in log of CFU/g of faeces
T i m e - B a c t e r i a / V o l .  n o . 12 34567 891 0 1 1 1 2
Day 0
Total Lactobacilli 1 × 106 7.5 × 105 1.6 × 105 1 × 105 1 × 106 9.3 × 104 7.6 × 107 5 × 105 4 × 104 2.6 × 106 6.8 × 106 1 × 107
L. paracasei-like 1.3 × 104 2.2 × 106 0 × 103 8.6 × 103 3 × 103 9 × 104 6.8 × 107 8 × 103 4 × 103 2.4 × 106 5.5 × 105 0 × 103
Bifidobacteria 8 × 108 3.7 × 108 0 × 106 3.5 × 109 9 × 107 1.8 × 108 1.5 × 109 4.6 × 106 0 × 104 2.2 × 109 3.4 × 107 1.6 × 109
Day 5
Total Lactobacilli 1.2 × 106 2.4 × 107 2.6 × 106 5 × 107 9.8 × 106 8.5 × 105 2.7 × 108 9.5 × 106 3.3 × 107 1.4 × 108 3.8 × 106 2.8 × 107
L. paracasei-like 1.5 × 106 2.3 × 107 2.1 × 106 3.9 × 107 9.5 × 106 8.3 × 105 2 × 108 9.5 × 106 2.7 × 107 1.4 × 108 3.4 × 106 1.7 × 107
Bifidobacteria 7.7 × 108 4.2 × 108 1.5 × 109 4.5 × 107 3.4 × 106 3 × 107 2.4 × 108 4.3 × 108 2.6 × 107 2.4 × 108 3.7 × 106 4.2 × 109
Day 10
Total Lactobacilli 4 × 105 2 × 108 8.3 × 106 2.8 × 107 3.2 × 106 2.2 × 106 4.1 × 108 1.6 × 107 8.6 × 107 9.7 × 105 7.5 × 106 7.6 × 106
L. paracasei-like 1.7 × 105 1.1 × 108 6.5 × 106 2.8 × 107 2.8 × 106 2.1 × 106 3.5 × 108 1.5 × 107 1.7 × 107 9.4 × 107 1 × 106 1 × 106
Bifidobacteria 9.2 × 108 1.4 × 1010 2.3 × 107 2.6 × 109 2.4 × 106 2.3 × 108 7.5 × 108 3.4 × 109 4.3 × 107 2.3 × 107 3.9 × 107 2.5 × 109
Day 15
Total Lactobacilli 6 × 106 3.7 × 108 9 × 106 2.5 × 107 1.5 × 107 2.8 × 106 4.4 × 108 5.9 × 108 3 × 107 1.5 × 108 5.7 × 105 4.1 × 106
L. paracasei-like 5.7 × 106 4.2 × 108 9 × 106 2.2 × 107 1.3 × 107 2.8 × 106 3.7 × 108 2 × 107 2 × 107 1.1 × 108 1.5 × 105 4.1 × 106
Bifidobacteria 4.6 × 109 1.4 × 1010 7.2 × 108 3.1 × 109 2.3 × 107 5.5 × 109 1.3 × 1010 2.9 × 108 3 × 107 3.5 × 109 2.6 × 108 2.6 × 107
Table 2: Viable bacterial counts from faecal samples at day 3 of post-treatment period. Individual values. Values are in log of CFU/g of 
faeces.
V o l u n t e e r  N . 1234567891 0 1 1 1 2
Total Lactobacilli 8.1 × 106 7.8 × 108 9.5 × 107 8.8 × 105 6.5 × 106 1.5 × 104 1.2 × 107 1.4 × 107 3 × 105 2.1 × 109 2.3 × 108 3.8 × 105
L. paracasei-like 1.5 × 106 4.8 × 108 1.9 × 106 8.5 × 104 2.8 × 105 1.5 × 104 1.1 × 107 1.2 × 107 1.5 × 105 6.4 × 106 2.3 × 106 3.1 × 104
Bifidobacteria 2 × 109 3.6 × 109 5.2 × 108 3.1 × 109 6.5 × 108 0 × 105 2.3 × 107 1 × 107 4 × 105 6.4 × 109 3.8 × 108 4.4 × 109Nutrition Journal 2003, 2 http://www.nutritionj.com/content/2/1/11
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In the present study, the ability of the probiotics strains to
survive through intestinal transit and persist after discon-
tinuation of intake was investigated in healthy volunteers.
An increase of faecal counts of vancomycin insensitive
group was consistently observed; in fact an increase of at
least one log in the counts of L. paracasei-like was found in
all subjects. A marked increase (>2–3 logs) was found in
subjects who had low counts of this group of lactobacilli
at baseline suggesting that the rate of growth of the
administered strains is even greater in subjects who have
reduced counts of this species and may be more exposed
to the adverse consequences of ecological imbalance.
The above change was already apparent after 5 days of
intake which suggests that potential probiotic benefits can
be obtained after only few days of intake.
Analysis of faecal samples after 3 days in the post-treat-
ment period shows that strains tend to persist as the
counts of L. paracasei group (which includes the adminis-
tered strains) are similar or only slightly decreased com-
pared to those achieved at the end of treatment and higher
than those observed at baseline.
Genotypic analysis confirmed that increase of strains phe-
notypically resembling L. paracasei group is related to
actual increase of L. paracasei species.
With regard to the effects on other intestinal bacteria, the
intake of the synbiotic preparation was accompanied by
an increase of bifidobacteria. This beneficial effect could
be related to the presence of oligosaccharide in the formu-
lation. No consistent effects were seen in other indigenous
bacteria, at least in those plate counted.
The tolerability of the preparation was excellent in all
individuals. No gastrointestinal or systemic adverse effects
were observed during the study
Conclusions
In this study we have shown that new human indigenous
probiotic strains of L. paracasei administered in a synbiotic
preparation can be recovered from the faeces of healthy
human volunteers and rapidly become the numerically
dominant Lactobacillus isolated in faecal samples. These
strains seems to persist in the colon for at least 3 days after
discontinuation of the oral intake. During the study a
favourable increase in total lactobacilli and bifidobacteria
was also found.
These results are very promising since the study on faecal
samples may underestimate colonization of colonic
mucosa by probiotic strains even if in the present study
microbiological analysis were made on fresh faecal sam-
ples. However the results of this study should be con-
ARDRA analysis Figure 1
ARDRA analysis from the left: Lane 1. Molecular Weight 
Marker (Roche)Lanes 2: CFU not identified as L. paracasei 
Lanes 3 to 8: CFUs identified as L. paracasei Lane 9: ARDRA 
of the reference strain DSM 5622T
Table 3: ARDRA identification of L. paracasei among the 
vancomycin insensitive lactobacilli. Values are expresses as 
positive identification/CFU analysed.
Synbiotic Intake Post-treatment
Vol. no. Day 10 Day 15 Day + 3
1 3 / 4 5 / 5 9 / 9
2 6 / 8 10 / 18 4 / 6
3 3 / 3 0 / 0 3 / 3
4 3 / 3 5 / 5 9 / 9
5 5 / 5 9 / 9 16 / 18
6 7 / 7 3 / 3 2 / 2
7 5 / 7 1 / 2 7 / 10
8 20 / 20 2 / 2 6 / 6
9 4 / 4 2 / 2 11/ 11
10 2 / 2 9 / 9 33 / 33
11 2 / 2 2 / 2 3 / 23
12 0 / 0 1 / 1 2 / 2
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firmed by further studies designed to determine the
minimum and optimal dose to achieve effective counts on
the colonic mucosa and including a more prolonged
period of observation to evaluate the actual duration of
persistence of these strains in the large intestine.
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